Drug Approval | April 09, 2025
Shilpa’s Unit-2 passes second consecutive FDA inspection with no 483s
Raichur site is the group’s largest API facility and part of a wider network of seven sites
Raichur site is the group’s largest API facility and part of a wider network of seven sites
This partnership encompasses dossier licensing, bulk product supply, and the licensing of ZIM Labs’ proprietary Oral Thin Film technology platform, ThinOral
This study enrolled a total of 204 healthy volunteers into three groups to compare BP16 with the reference products, Prolia, obtained from both the EU and US markets
Introduces revolutionary approach to workflow management to enhance operational efficiency and optimize process efficiency
NATCO has decided to price the product at Rs.15, 900 MRP consistent with the company’s stand before the court
Nadda noted that on the basis of economic caste census, 50 crore people were brought under this scheme
Findings likely to generate hypotheses about potential new uses of drugs
Increases Siemens’ industrial software total addressable market by $11 billion; aligns with strategic goal to accelerate customer innovation across industries
Fexuprazan has the longest half-life of 9 hours among potassium-competitive acid blockers
Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease
Subscribe To Our Newsletter & Stay Updated
